Liver-expressed antimicrobial peptide 2

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Agencia Estatal de Investigación and 6 more

Animals1

Outcomes

Steatosis

no changein mice1

1 study

Liver-expressed antimicrobial peptide 2 has no effect on steatosis in mice.
“LEAP2 did not prevent high-fat diet-induced steatosis in young mice”
Animalsin high-fat diet-fed young miceliver
LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging
Life sciences20 Jan 2026

Latest

1 in 12 months

Life Sciences23 Jan

LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging

Experiments in miceHepatic steatosis

Paper

Liver-expressed antimicrobial peptide 2

Outcomes

Latest

LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging

Related